The IDKmonitor^® Infliximab Free ADA ELISA is intended to qualitatively determine free human antibodies against Infliximab (e.g., REMICADE^®) in EDTA plasma and serum.

Health Canada Licensed. For Laboratory Professional Use Only.

Not for sale in the U.S. Please contact us to order or get a quote.

If you are in the U.S., you can purchase the RUO version of the Infliximab Free ADA ELISA.

Browse our other IDKmonitor^® Infliximab ELISAs.

Test Principle of the IDKmonitor^® Infliximab Free ADA ELISA

The IDKmonitor^® Infliximab Free ADA ELISA is designed for the determination of free antibodies against Infliximab (e. g. REMICADE®).

In the first incubation step, the free anti-infliximab antibodies from the sample are bound to the infliximab F(ab)2 fragments coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, a peroxidase-labeled therapy antibody is added. After another washing step to remove all unbound substances, the solid phase is incubated with a tetramethylbenzidine (TMB) substrate. An acidic stop solution is then added.

The color converts to yellow. The absorbance of the color compound is determined photometrically at 450 nm. The intensity of the color is directly proportional to the amount of bound anti-infliximab antibodies (e.g., REMICADE®) from the sample. The results are evaluated by a cut-off control.